| Identification | Back Directory | [Name]
Glycogen Phosphorylase Inhibitor | [CAS]
648926-15-2 | [Synonyms]
Glycogen Phosphorylase Inhibitor
2-chloro-4,5-difluoro-N-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide | [Molecular Formula]
C17H15ClF2N4O4 | [MDL Number]
MFCD22050364 | [MOL File]
648926-15-2.mol | [Molecular Weight]
412.78 |
| Chemical Properties | Back Directory | [density ]
1.490±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF:5.0(Max Conc. mg/mL);12.11(Max Conc. mM)
DMSO:5.0(Max Conc. mg/mL);12.11(Max Conc. mM) | [form ]
White powder solid. | [pka]
8.47±0.46(Predicted) | [color ]
white | [InChI]
1S/C17H15ClF2N4O4/c1-21-16(26)22-8-3-4-14(28-2)13(5-8)23-17(27)24-15(25)9-6-11(19)12(20)7-10(9)18/h3-7H,1-2H3,(H2,21,22,26)(H2,23,24,25,27) | [InChIKey]
ROJNYKZWTOHRNU-UHFFFAOYSA-N | [SMILES]
Fc1c(cc(c(c1)Cl)C(=O)NC(=O)Nc2c(ccc(c2)NC(=O)NC)OC)F |
| Hazard Information | Back Directory | [Description]
Glycogen phosphorylase in the liver, muscle, and brain initiate glycogenolysis by releasing glucose-1-phosphate from glycogen. Glycogen phosphorylase inhibitor is a cell-permeable acyl urea first identified as an inhibitor of human liver glycogen phosphorylase (IC50 = 53 nM). It blocks glucagon-induced hepatic glycogenolysis in vivo. Glycogen phosphorylase inhibitor has been used to study glycogen utilization in human liver HepG2 cells, retinal explants, and human T lymphocyte Kit 225 cells. | [Uses]
Glycogen Phosphorylase Inhibitor is used in biological studies to evaluate glycogen utilization in human liver HepG2 cells. | [in vivo]
Glycogen phosphorylase-IN-1 (5 mg/kg, i.v., single dose) inhibits the glycogenolysis in hepatocytes, ameliorates the glucagon stimulated hyperglycemic in wistar rats[1]. | Animal Model: | Glucagon-stimulated hyperglycemic in wistar rats[1] | | Dosage: | 5 mg/kg | | Administration: | i.v., single dose | | Result: | Reduced blood glucose. |
| [References]
[1] THOMAS KLABUNDE. Acyl Ureas as Human Liver Glycogen Phosphorylase Inhibitors for the Treatment of Type 2 Diabetes[J]. Journal of Medicinal Chemistry, 2005, 48 20: 6178-6193. DOI: 10.1021/jm049034y
[2] ALAN CHENG. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori’s disease.[J]. Genes & development, 2007, 21 19: 2399-2409. DOI: 10.1101/gad.1553207
[3] KONSTANTINOS PAPPELIS. The retinal ganglion cells in metabolic syndrome.[J]. Annals of translational medicine, 2024, 12 1: 2. DOI: 10.21037/atm-23-1796
[4] ONETSINE ARRIZABALAGA. Rac1 protein regulates glycogen phosphorylase activation and controls interleukin (IL)-2-dependent T cell proliferation.[J]. The Journal of Biological Chemistry, 2012: 11878-11890. DOI: 10.1074/jbc.m111.297804 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
amyjet
|
| Tel: |
4006800868;027-59626688 18371453821;18771149750 |
| Website: |
http://www.amyjet.com/ |
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|